{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:11:38Z","timestamp":1790892698796,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1038\/s41431-021-01004-7","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T21:02:26Z","timestamp":1637010146000},"page":"1114-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-716X","authenticated-orcid":false,"given":"Jurriaan M. J. L.","family":"Brouwer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7476-6867","authenticated-orcid":false,"given":"Marga","family":"Nijenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Soree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-5552","authenticated-orcid":false,"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan van der","family":"Weide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard A. P. J. M.","family":"Rongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Buunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke J.","family":"de Boer-Veger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9927-7266","authenticated-orcid":false,"given":"Elisa J. F.","family":"Houwink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos","family":"van Westrhenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Wilffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera H. M.","family":"Deneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"1004_CR1","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1371\/journal.pmed.0040209","volume":"4","author":"JJ Swen","year":"2007","unstructured":"Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 2007;4:1317\u201324.","journal-title":"PLoS Med"},{"key":"1004_CR2","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","volume":"89","author":"JJ Swen","year":"2011","unstructured":"Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharm Ther. 2011;89:662\u201373.","journal-title":"Clin Pharm Ther"},{"key":"1004_CR3","unstructured":"CPIC\u00ae Guideline for Selective Serotonin Reuptake Inhibitors and CYP2D6 and CYP2C19 \u2013 CPIC. https:\/\/cpicpgx.org\/guidelines\/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19\/ [Accessed February 2021]."},{"key":"1004_CR4","doi-asserted-by":"crossref","unstructured":"van Westrhenen R, van Schaik RHN, van Gelder T, Birkenhager TK, Bakker PR, Houwink EJF, et al. Policy and Practice Review: a First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice. Front Pharmacol. 2021;12:640032.","DOI":"10.3389\/fphar.2021.640032"},{"key":"1004_CR5","doi-asserted-by":"crossref","unstructured":"van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Juki\u0107 MM. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going? Front Psychiatry. 2020;11:94.","DOI":"10.3389\/fpsyt.2020.00094"},{"key":"1004_CR6","unstructured":"CYP2C19 cytochrome P450 family 2 subfamily C member 19 [Homo sapiens (human)] - Gene - NCBI. https:\/\/www.ncbi.nlm.nih.gov\/gene\/1557."},{"key":"1004_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000028398","volume":"61","author":"PJ Wedlund","year":"2000","unstructured":"Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology. 2000;61:174\u201383.","journal-title":"Pharmacology."},{"key":"1004_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharm Ther. 2006;79:103\u201313.","journal-title":"Clin Pharm Ther"},{"key":"1004_CR9","unstructured":"Pharmacogene Variation Consortium: CYP2C19. https:\/\/www.pharmvar.org\/gene\/CYP2C19. [Accessed June 2019]."},{"key":"1004_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharm Ther. 2013;94:317\u201323.","journal-title":"Clin Pharm Ther"},{"key":"1004_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00228-006-0183-2","volume":"62","author":"M Kurzawski","year":"2006","unstructured":"Kurzawski M, Gawro\u0144ska-Szklarz B, Wrze\u015bniewska J, Siuda A, Starzy\u0144ska T, Dro\u017adzik M. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharm. 2006;62:877\u201380.","journal-title":"Eur J Clin Pharm"},{"key":"1004_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1365-2125.2007.03057.x","volume":"65","author":"K Sugimoto","year":"2008","unstructured":"Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharm. 2008;65:437\u20139.","journal-title":"Br J Clin Pharm"},{"key":"1004_CR13","doi-asserted-by":"crossref","unstructured":"Matic M, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur J Hum Genet. 2021. Online ahead of print.","DOI":"10.1038\/s41431-021-00969-9"},{"key":"1004_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018;51:9\u201362.","journal-title":"Pharmacopsychiatry"},{"key":"1004_CR15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","volume":"161","author":"JH Meyer","year":"2004","unstructured":"Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826\u201335.","journal-title":"Am J Psychiatry"},{"key":"1004_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/009127000004000108","volume":"40","author":"CL Alfaro","year":"2000","unstructured":"Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharm. 2000;40:58\u201366.","journal-title":"J Clin Pharm"},{"key":"1004_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00004714-199904000-00011","volume":"19","author":"CL Alfaro","year":"1999","unstructured":"Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol. 1999;19:155\u201363.","journal-title":"J Clin Psychopharmacol"},{"key":"1004_CR18","doi-asserted-by":"crossref","unstructured":"Swen JJ, Wilting I, Goede AL De, Grandia L, Mulder H, Touw DJ, et al. Pharmacogenetics: From bench to byte. Vol. 83, Clinical Pharmacology and Therapeutics. Nature Publishing Group; 2008;83:781\u20137.","DOI":"10.1038\/sj.clpt.6100507"},{"key":"1004_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41397-021-00249-1","volume":"21","author":"K Karamperis","year":"2021","unstructured":"Karamperis K, Koromina M, Papantoniou P, Skokou M, Kanellakis F, Mitropoulos K, et al. Economic evaluation in psychiatric pharmacogenomics: a systematic review. Pharmacogenomics J. 2021;21:533\u201341.","journal-title":"Pharmacogenomics J"},{"key":"1004_CR20","doi-asserted-by":"crossref","unstructured":"Simeonidis S, Koutsilieri S, Vozikis A, Cooper DN, Mitropoulou C, Patrinos GP. Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions. Front Pharmacol. 2019;10:830.","DOI":"10.3389\/fphar.2019.00830"},{"key":"1004_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2015.11.008","volume":"54","author":"CATC Lunenburg","year":"2016","unstructured":"Lunenburg CATC, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JHM, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer. 2016;54:40\u20138.","journal-title":"Eur J Cancer"},{"key":"1004_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/cpt.1049","volume":"103","author":"JJ Swen","year":"2018","unstructured":"Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF, et al. Pharmacogenetic Information in Clinical Guidelines: The European Perspective. Clin Pharm Ther. 2018;103:795\u2013801.","journal-title":"Clin Pharm Ther"},{"key":"1004_CR23","unstructured":"Leidraad farmacogenetica voor de dagelijkse psychiatrische praktijk. https:\/\/www.nvvp.net\/website\/nieuws\/2020\/leidraad-farmacogenetica-voor-de-dagelijkse-psychiatrische-praktijk."},{"key":"1004_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/cpt.762","volume":"103","author":"PCD Bank","year":"2018","unstructured":"Bank PCD, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, Klein TE, et al. Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin Pharmacol Ther Nat Publ Group. 2018;103:599\u2013618.","journal-title":"Clin Pharmacol Ther Nat Publ Group"},{"key":"1004_CR25","doi-asserted-by":"crossref","unstructured":"Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. Front Pharmacol. 2021;11:595219.","DOI":"10.3389\/fphar.2020.595219"},{"key":"1004_CR26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00228-008-0533-3","volume":"64","author":"I Rudberg","year":"2008","unstructured":"Rudberg I, Hermann M, Refsum H, Molden E. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharm. 2008;64:1181\u20138.","journal-title":"Eur J Clin Pharm"},{"key":"1004_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/sj.clpt.6100291","volume":"83","author":"I Rudberg","year":"2008","unstructured":"Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharm Ther. 2008;83:322\u20137.","journal-title":"Clin Pharm Ther"},{"key":"1004_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13:116\u201324.","journal-title":"Clin Transl Sci"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-021-01004-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-021-01004-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-021-01004-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T10:03:23Z","timestamp":1665482603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-021-01004-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1004"],"URL":"https:\/\/doi.org\/10.1038\/s41431-021-01004-7","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"assertion":[{"value":"9 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research involves a literature research and no human subjects, human material, or human data. Therefore, no approval by an ethics committee was needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}